Noscapine - KineMed
Latest Information Update: 25 Apr 2023
Price :
$50 *
At a glance
- Originator Emory University
- Developer KineMed
- Class Alkaloids; Antineoplastics; Antitussives; Isoquinolines; Opiate alkaloids; Small molecules
- Mechanism of Action Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (PO)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (PO)
- 04 Sep 2014 Preclinical trials in Amyotrophic lateral sclerosis in USA (PO)